Liver health may impact how Weight-Loss drug works

NCT ID NCT05564104

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests how the experimental drug cagrilintide, being developed for weight management, is processed by the body in people with different levels of liver function. It involves 32 participants, including those with liver impairment and healthy volunteers. The goal is to see if liver problems change how the drug is absorbed and eliminated, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cagrilintide
What this could lead to: If successful, this study could help ensure that cagrilintide is used safely and effectively in people with liver problems for weight management.
What could go wrong: This is an early-phase study with only 32 participants, focused on drug processing rather than weight loss. Results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEPATIC IMPAIRMENT

Contacts and locations

Locations

APEX Research

München, 81241, Germany
Pharmaceutical Research Associates CZ, s.r.o.

Prague, 17000, Czechia
Summit Clinical Research s.r.o.

Bratislava, 83101, Slovakia
Summit Clinical Research s.r.o.

Malacky, 901 22, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.